Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation

被引：52

作者：

Fountzilas, George ^{[8
]}

Bobos, Mattheos

Kalogera-Fountzila, Anna

Xiros, Nikolaos ^{[1
]}

Murray, Samuel ^{[2
]}

Linardou, Helena ^{[2
]}

Karayannopoulou, Georgia

Koutras, Angelos K. ^{[3
]}

Bafaloukos, Dimitrios ^{[2
]}

Samantas, Epaminondas ^{[4
]}

Christodoulou, Christos ^{[5
]}

Economopoulos, Theofanis ^{[1
]}

Kalogeras, Konstantine T. ^{[6
]}

Kosmidis, Paris ^{[7
]}

机构：

[1] Univ Gen Hosp Attikon, Athens, Greece

[2] Metropolitan Hosp, Piraeus, Greece

[3] Univ Hosp Patras, Patras, Greece

[4] Agii Anargiri Canc Hosp, Athens, Greece

[5] Henry Dunant Hosp, Athens, Greece

[6] Hellen Cooperat Oncol Grp Data Off, Athens, Greece

[7] Hygeia Hosp, Athens, Greece

[8] Aristotle Univ Thessaloniki, Sch Med, PAPAGEORGIOU Hosp, Dept Med Oncol, Thessaloniki, Macedonia, Greece

来源：

CANCER INVESTIGATION | 2008年 / 26卷 / 08期

关键词：

chemotherapy; gefitinib; gemcitabine; pancreatic cancer;

D O I：

10.1080/07357900801918611

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The combination of gemcitabine and gefitinib was evaluated in advanced pancreatic cancer. Totally, 53 patients were treated with a 7 week cycle of gemcitabine (1,000 mg/m2 given weekly) followed by six 4 week cycles of gemcitabine given on days 1, 8 and 15. Gefitinib 250 mg was administered daily. Responses were seen in 6, and stabilization of the disease in 12 patients. The main toxicity was myelotoxicity (92%). The 6-month progression-free survival (PFS) was 30%. Median PFS was 4.1 months and median survival 7.3 months with a 1 year survival rate of 27%. The above combination demonstrated promising activity in advanced pancreatic cancer.

引用

页码：784 / 793

页数：10

共 42 条

[1] Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer [J].

Abou-Alfa, Ghassan K. ;

Letourneau, Richard ;

Harker, Graydon ;

Modiano, Manuel ;

Hurwitz, Herbert ;

Tchekmedyian, Nerses Simon ;

Feit, Kevie ;

Ackerman, Judie ;

De Jager, Robert L. ;

Eckhardt, S. Gail ;

O'Reilly, Eileen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4441-4447

[2] COMPREHENSIVE CRITERIA FOR ASSESSING THERAPY-INDUCED TOXICITY [J].

AJANI, JA ;

WELCH, SR ;

RABER, MN ;

FIELDS, WS ;

KRAKOFF, IH .

CANCER INVESTIGATION, 1990, 8 (02) :147-159

[3] The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells [J].

Asano, T ;

Yao, YX ;

Zhu, JJ ;

Li, DH ;

Abbruzzese, JL ;

Reddy, SAG .

ONCOGENE, 2004, 23 (53) :8571-8580

[4]

Bruns CJ, 2000, CANCER RES, V60, P2926

[5]

Bruns CJ, 2000, CLIN CANCER RES, V6, P1936

[6]

CASCINU S, 2007, J CLIN ONCOL S18, V25

[7]

Choe G, 2003, CANCER RES, V63, P2742

[8] RETRACTED: Potentiation of the effect of erlotinib by genistein in pancreatic cancer:: The role of Akt and nuclear factor-κB (Retracted article. See vol. 78, pg. 5472, 2018) [J].

El-Rayes, Basil F. ;

Ali, Shadan ;

Ali, Ifrah F. ;

Philip, Philip A. ;

Abbruzzese, James ;

Sarkar, Fazlul H. .

CANCER RESEARCH, 2006, 66 (21) :10553-10559

[9]

Fernandez M, 2002, CLIN CANCER RES, V8, P1695

[10]

Fountzilas G, 2006, ANTICANCER RES, V26, P4675

← 1 2 3 4 5 →